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 Trent Development and Evaluation Committee 
 
The purpose of the Trent Development and Evaluation Committee is to help health authority and 
other purchasers within the Trent Region by commenting on expert reports which evaluate 
changes in health service provision. The Committee is comprised of members appointed on the 
basis of their individual knowledge and expertise, and includes non-clinically qualified scientists 
and lay members. It is chaired by Professor Sir David Hull. 
 
The committee recommends, on the basis of appropriate evidence, priorities for: 
x the direct development of innovative services on a pilot basis; 
x service developments to be secured by health authorities. 
 
The statement that follows was produced by the Development and Evaluation Committee at its 
meeting on 22 July 1997 at which this Guidance Note for Purchasers (in a draft form) was 
considered. 
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SUMMARY:  
Carcinoma of the ovary is the commonest gynaecological malignancy and the fourth most 
common cause of cancer death in women. There are approximately 450 cases of ovarian cancer 
reported annually in the Trent region, giving an annual incidence rate of around 19 per 100,000 
women. Chemotherapy combinations that include an alkylating agent and a platinum analogue 
(i.e. cisplatin, carboplatin) have been demonstrated to have high response rates in women with 
advanced ovarian cancer. Single agent carboplatin is the most widely used regime in the UK. A 
single phase III RCT has reported a median survival of 38 months for paclitaxel/cisplatin and 24 
months for the cisplatin/cyclophosphamide (US baseline treatment). 
 
An economic analysis of the treatment calculated that the introduction of paclitaxel/cisplatin 
treatment programme for an average district (500,000) population would cost £258,368 per year. 
The treatment is expected to give each patient an average of 1.17 years extra survival at a cost of 
£7,200 per life year gained. 
 
DECISION: The Committee recommended that Paclitaxel should be available for 
patients within national controlled trials. Some members felt it should be limited only to 
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should be available for other patients at the discretion of the clinicians. This decision 
should be reviewed when more evidence is made available from the trials in hand. 
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 ABOUT THE TRENT INSTITUTE FOR HEALTH SERVICES RESEARCH 
 
The Trent Institute for Health Services Research is a collaborative venture between the 
Universities of Leicester, Nottingham and Sheffield with support from NHS Executive Trent.  
 
The Institute: 
 
x provides advice and support to NHS staff on undertaking Health Services Research 
(HSR); 
  
x provides a consultancy service to NHS bodies on service problems; 
  
x provides training in HSR for career researchers and for health service professionals; 
  
x provides educational support to NHS staff in the application of the results of research; 
  
x disseminates the results of research to influence the provision of health care. 
 
The Directors of the Institute are: Professor R L Akehurst (Sheffield); 
     Professor C E D Chilvers (Nottingham); and  
     Professor M Clarke (Leicester).  
Professor Akehurst currently undertakes the role of Institute Co-ordinator. 
 
A Core Unit, which provides central administrative and co-ordinating services, is located in 
Regent Court within the University of Sheffield in conjunction with the School of Health and 
Related Research (ScHARR). 
 FOREWORD 
 
A network exists in the Trent Region where purchasers can share research knowledge 
about the effectiveness and cost-effectiveness of acute service interventions and determine 
collectively their purchasing policy. 
 
ScHARR, which houses the Sheffield Unit of the Trent Institute for Health Services 
Research, facilitates a Working Group on Acute Purchasing. A list of interventions for 
consideration is recommended by the purchasing authorities in Trent and approved by the 
Purchasing Authorities Chief Executives (PACE) and the Trent Development and Evaluation 
Committee (DEC). A public health consultant from a purchasing authority leads on each 
topic and is assisted by a support team from ScHARR, led by Dr Nick Payne, Senior 
Lecturer in Public Health Medicine, which provides help including literature searching, health 
economics and modelling. A seminar is then led by the consultant on the particular 
intervention where purchasers and provider clinicians consider research evidence and agree 
provisional recommendations on purchasing policy. The guidance emanating from the 
seminars is reflected in this series of Guidance Notes which have been ratified by the Trent 
DEC which is chaired by Professor Sir David Hull. 
 
7KH 7UHQW ,QVWLWXWH¶V :RUNLQJ *URXS RQ $FXWH 3XUFKDVLQJ LV SDUW RI D ZLGHU FROODERUDWLRQ
working with three units in other regions (The Wessex Institute for Health Research and 
Development, The Scottish Health Purchasing Information Centre (SHPIC) and The 
Birmingham University Institute for Public and Environmental Health) to share this work on 
reviewing the effectiveness and cost-effectiveness of clinical interventions. This group, 
InterDEC, will share this work, avoid duplication and improve the peer reviewing and quality 
control of these reports. 
 
 
 
 
 
 
 
 
Professor R L Akehurst, 
Chairman, Trent Working Group on Acute Purchasing. 
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EXECUTIVE SUMMARY 
 
Carcinoma of the ovary is the commonest gynaecological malignancy and the fourth most 
common cause of cancer death in women. Around half of cases occur in women aged 65 or 
over. Whilst many clinical trials have been published previously concerning the treatment of 
advanced ovarian cancer, only one randomised controlled trial (RCT) exists which has fully 
reported on the use of cisplatin in combination with paclitaxel, specifically as a first line 
treatment. 
 
There are approximately 450 cases of ovarian cancer reported annually in the Trent region, 
giving an annual incidence rate of around 19 per 100,000 women. Trent figures indicate that 
49% of cases are in women over the age of 65. 
 
Chemotherapy combinations that include an alkylating agent and a platinum analogue have 
been demonstrated to have high response rates in women with advanced ovarian cancer.  
Single agent carboplatin is the most widely used regime in the UK.1  
 
7KHVDXUXV VHDUFKHV RI 0HGOLQH XVLQJ 0H6+ WHUPV µSDFOLWD[HO¶ DQG µRYDULDQ QHRSODVPV¶
DQG (PEDVH XVLQJ WHUPV µSDFOLWD[HO¶ DQG µRYDU\ FDQFHU¶ OLPLWHG WR LGHQWLI\ UDQGRPLVHG
controlled trials, reveal only one RCT comparing paclitaxel with a standard treatment regime 
- the Gynecologic Oncology Group (GOG) trial.2 
 
On the basis of our analysis, based on the GOG trial, there appears to be a definite clinical 
benefit from the use of paclitaxel/cisplatin (TP) combination therapy in the first line treatment 
of ovarian cancer, although this is still very much based on the results of a single phase III 
RCT. Median survival statistics as published indicate 38 months for paclitaxel/cisplatin and 
24 months for the cisplatin/cyclophosphamide US baseline treatment. 
 
Put into the context of the Trent region prevalence rates and female population, an 
economic analysis of the treatment implies an increase in total treatment costs of just under 
£2.5 million per annum. For an average district of 250,000 females this equates to an 
increase of around £258,368. 
 
In terms of extra life years gained (LYG) the treatment is expected to give each patient an 
average of 1.17 years extra survival. This equates to a cost per extra LYG of approximately 
£7,200, which compares favourably with similar cost per life year gained figures for other 
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treatments and falls below the threshold of £20,000 per LYG which is often used and 
referred to. 
 
A recent Wessex DEC Report3 has also independently recommended the use of 
paclitaxel/cisplatin as a first line treatment option, along with the current standard treatments 
of carboplatin and cyclophosphamide/doxorubicin/cisplatin. However, a review of this 
recommendation was also advised after the publication of further trial evidence. 
 
Supportive evidence from an economic evaluation conducted by the GOG trial produced 
comparable results when costing treatment benefits in the context of the US marketplace. 
 
A number of RCTs are currently ongoing exploring further the use of first line paclitaxel and 
considering uses in combination with carboplatin and with dosage variation. 
 
In terms of options for purchasers, it is concluded that there is certainly a strong enough 
body of evidence for the continued support of ongoing RCTs into paclitaxel, via the ICON 31 
trial recruitment (although this is limited to 2,000 patients). It is also felt that given further 
supporting evidence, from the interim results of the EORTC Inter-Group trial4 the first line 
use of paclitaxel should be funded in conjunction with other existing standard treatments.  
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1. INTRODUCTION 
 
Carcinoma of the ovary is the commonest gynaecological malignancy and the fourth most 
common cause of cancer death in women. Around half of cases occur in women aged 65 or 
over. Whilst many clinical trials evaluating cytotoxic treatment regimes for ovarian cancer 
have been published, only one Randomised Controlled Trial (RCT) exists which has fully 
reported on the use of paclitaxel as a first line treatment. This trial was conducted by the 
Gynecologic Oncology Group (GOG)2 and focused in particular on the therapy of cisplatin in 
combination with paclitaxel. This paper examines the clinical evidence for the effectiveness 
of the paclitaxel/cisplatin (TP) platinum combination and relates this to the expected costs of 
such a treatment.  
 
1.1 Incidence and Pathology 
 
There are approximately 450 cases of ovarian cancer reported annually in the Trent region, 
giving an annual incidence rate of around 19 per 100,000 women. Trent figures indicate that 
49% of cases are in women over the age of 65, based on average values 1990-93. The 
mean and modal age at presentation lie between 60 and 64 years. 
 
The natural history of the disease is characterised by an insidious onset with vague non-
specific symptoms, and a high, although often transient, response to surgery and 
chemotherapy. As ovarian cancer is often asymptomatic in its early stages, most patients 
have widespread disease at the time of diagnosis.   
 
Table 1: Disease Stage at Diagnosis2 
 
 STAGE I(%) STAGE II(%) STAGE III(%) STAGE IV(%) 
OVARY 10 8 60 17 
 
Ovarian cancer spreads via local shedding into the peritoneal cavity followed by implantation 
on the peritoneum, via local invasion of bowel and bladder, or via the abdominal lymphatics. 
 
 
 
1.2 Prognosis and Mortality 
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In Trent, between 1989 and 1993, 42% of patients died in the first year after diagnosis.  
Overall 32% of patients survived into their third year after diagnosis.5 
 
International Federation of Obstetricians and Gynaecologists (FIGO) data provide 
information on survival by disease stage at presentation. 6 
 
Table 2: Five Year Survival Rates2 
 
 STAGE I(%) STAGE II(%) STAGE III(%) STAGE IV(%) OVERALL 
FIGO STAGE 85 50 25 5 32.7 
 
Prognosis is influenced by several factors.  Good prognostic factors include younger age, 
good performance or functional status, cell type other than mucinous and clear cell, early 
stage at presentation, well differentiated tumour, small disease volume prior to any surgical 
debulking and the absence of ascites.7 
 
Early-stage ovarian cancer is readily controlled by resection and chemotherapy.  Extensive 
debulking surgery and multi-agent chemotherapy, show significant, although still modest, 
improvements in the survival of advanced-stage cancer.  The incidence of positive nodes at 
primary surgery has been reported as high as 24% in stage I, 50% in stage II, 74% in stage 
III, and 73% in stage IV.8 
 
Chemotherapy combinations that include an alkylating agent and a platinum analogue have  
demonstrated high response rates in women with advanced ovarian cancer. However, these 
combinations provide long-term control of the disease in only a small number of patients.9  
After two influential meta-analyses found no difference in survival between cisplatin and 
carboplatin, treatment for women focused on single agent carboplatin in the UK. Although 
carboplatin is substantially more expensive than cisplatin it is much better tolerated, with 
less renal, gastro-intestinal and neurological toxicity, and is suitable for out-patient 
administration.10,11  The main dose limiting toxicity of carboplatin is myelosuppression, and 
this may make its use in combination with other myelosuppressive agents more difficult.12   
 
The disease will recur in approximately 30%-50% of patients with a pathologically confirmed 
complete response to chemotherapy.13 The risk of recurrence in patients treated with 
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platinum-based combination chemotherapy is directly related to stage, histological grade, 
and amount of tumour remaining after first operation.14 
 
1.3 Current Standard Treatment Options 
 
The following section details the current treatment options for ovarian cancer organised by 
disease stage. 
 
1.3.1 Stage I  
 
Surgery alone is usually considered adequate for stages IA and IB (total abdominal 
hysterectomy and bilateral salpingo-oophorectomy with omentectomy) if tumour is well or 
moderately well differentiated. 
 
Patients with poorly differentiated stage 1A or 1B may be treated with chemotherapy in 
addition to surgery. 
 
1.3.2 Stages Ic, II, III and IV  
 
Therapy for these stages of ovarian cancer is largely palliative. Treatment is based initially 
on surgery (total abdominal hysterectomy and bilateral salpingo-oophorectomy and tumour 
debulking and omentectomy) to remove all or most of the tumour.  Surgery is followed by 
adjuvant chemotherapy for those patients with good performance status. 
 
Single agent carboplatin is the most widely used regime in the UK.1  
 
Alternative regimes include :- 
x cyclophosphamide/cisplatin (CP) 
x cyclophosphamide/doxorubicin/cisplatin (CAP) 
x cyclophosphamide/carboplatin 
 
However, in the USA the current first line treatment is now firmly established as 
paclitaxel/cisplatin. This follows the recent results from the GOG 111 trial.  
1.4 6FDOHRI3UREOHPLQDµ7\SLFDO¶District 
 
In a typical district of 500,000 people (250,000 females), approximately 47 newly reported 
cases of ovarian cancer would be expected each year.  
 6 
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2. USE OF PACLITAXEL IN THE TREATMENT OF OVARIAN CANCER 
 DISEASE : SUMMARY OF EVIDENCE OF EFFECTIVENESS 
 
2.1 Summary of Evidence for the Effectiveness of Paclitaxel 
 
2.1.1 Mechanism of Action 
 
Paclitaxel is a mitotic inhibitor with a novel mechanism of action. It promotes polymerisation 
of tubulin dimers to form microtubules and also stabilises microtubules by preventing 
depolymerisation. The drug is unique amongst chemotherapeutic agents in having a specific 
binding point on the microtubule.15 
 
Paclitaxel microtubules are stable in conditions that usually promote tubule disassembly.  
Prolonged infusion produces distinct changes in cell morphology which adversely affect 
microtubule function during both interphase and mitosis.  The precise reasons for cell death 
are unclear.16 
 
The entire mechanism of systemic clearance is not known. Hepatic metabolism is significant 
and biliary deposition accounts for 20% (paclitaxel) and 40% (metabolites) of drug 
administered. Urinary excretion is 5-10%. 
 
The most significant complications of the drug include allergic reactions, neutropenia and 
peripheral neuropathy.17 
 
2.1.2 Paclitaxel as an Adjuvant Primary Therapy for Stages III and IV Ovarian 
 Cancer 
 
7KHVDXUXV VHDUFKHV RI 0HGOLQH XVLQJ 0H6+ WHUPV µSDFOLWD[HO¶ DQG µRYDULDQ QHRSODVPV¶
DQG (PEDVH XVLQJ WHUPV µSDFOLWD[HO¶ DQG µRYDU\ FDQFHU¶ OLPLWHG WR LGHQWLI\ UDQGRPLVHG 
controlled trials, reveal only one RCT comparing paclitaxel with a standard treatment regime 
- the GOG trial.2 It is unlikely that such a trial will be repeated in the USA.  Combination 
therapy with paclitaxel is now seen as standard therapy there.  In addition, as the authors 
point out, this trial was carried out when supplies of paclitaxel were difficult to obtain, and 
this was felt to minimise the crossover effect common in US trials when patients actively 
seek new and promising therapies and drop out of a trial, or receive the test agent on 
relapse. In the UK the MRC established the ICON 31 trial to compare paclitaxel/carboplatin, 
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carboplatin alone and combination cyclophosphamide/doxorubicin/cisplatin. This trial 
continues to recruit patients. 
 
2.1.3 The Gynecologic Oncology Group Trial 
 
The GOG in the USA established a multi-centre randomised phase 3 trial to compare two 
combinations of chemotherapy, cisplatin and cyclophosphamide versus cisplatin and 
paclitaxel, in women with incompletely resected stage III or any stage IV ovarian cancer. It 
began recruiting in April 1990. 410 women with advanced ovarian cancer and residual 
masses larger than 1 cm after initial surgery were randomised to receive cisplatin (75 mg 
per square metres of body-surface area) with either cyclophosphamide (CP) (750 mg per 
square metre) or paclitaxel (TP) (135 mg per square metre over 24 hours). The trial authors 
concluded that incorporating paclitaxel into first-line therapy improved the duration of 
progression-free survival and of overall survival in women with incompletely resected stage 
III and stage IV ovarian cancer. 
 
2.1.4 Eligibility 
 
Only women with incompletely resected stage III (>1cm residual mass) or any stage IV 
ovarian cancer were recruited i.e. those in the worst prognostic group. Trial eligibility criteria 
were: no previous chemotherapy, good performance status, normal renal and liver function 
and a white cell count of at least 3,000 per cubic millimetre. Women with a history of cardiac 
arrhythmias were excluded. Trial entry was within six weeks of surgery. 
 
No study power calculation is referred to. The trial recruited only 400 women. However, 
given the relatively low incidence of the disease, this represents a major achievement. 
Women were randomised with equal probability after stratification by institution and for the 
extent of clinical disease. 
 
,IDZRPDQ¶VZKLWHFHOO FRXQW IHOOEHORZSHUFXELFPLOOLPHWUHRUSODWHOHW FRXQWEHORZ
100,000 per cubic millimetre, treatment was delayed. If the delay exceeded three weeks, 
these women were withdrawn from the study. Severe neurological, otic or renal toxicity and 
cardiac toxic events were grounds for ceasing therapy but with continued trial follow-up. No 
reduction in cisplatin dose was allowed. Dose reduction for paclitaxel and cyclophosphamide 
was based on white blood cell count or platelet counts. 
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2.1.5 Outcome Measures 
 
The main outcome measure of the study was a reduction in measurable disease extent.  
Assessment was not blinded. Clinical response was measured in accordance with WHO 
guidance.18  This included a re-assessment laparotomy for those women without clinically 
measurable disease. 
 
Progression free survival was measured from randomisation. Survival was measured up to 
date of death or last contact. 
 
2.1.6 Population 
 
Three hundred and eighty-six women met all the eligibility criteria. The oldest woman in the 
trial was 84. There was an imbalance in prognostic factors between the two arms of the trial.  
In any randomisation process this is to be expected and none of the differences was 
statistically significant. In the CP arm there were 12 per cent fewer patients with serous 
adenocarcinoma, 64% as against 76% . Conversely, there was almost double the proportion 
of grade 1 tumours, 7% as against 4%. Stage tended to be more advanced and extent of 
disease (as measurable disease) worse in the CP group. 
 
2.1.7 Withdrawals 
 
21 (10%) women in the standard regime and 15 (8%) in the paclitaxel group failed to 
complete six cycles of therapy because of choice or toxicity. In total 201 women received CP 
and 184 TP.   
 
Interestingly, 23 (11%) women failed to complete the standard regime because of disease 
progression or death compared to 9 (5%) in the paclitaxel group.   
 
Alopecia, neutropenia, fever, and allergic reactions were significantly greater in the TP 
group although the clinical significance of this is difficult to gauge from the published tables. 
There were 10 treatment related deaths (6 CP and 4 TP). 
 
2.1.8 Major End-point 
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Among the cohort of 216 women with measurable disease, 73% in the paclitaxel/cisplatin 
group responded to therapy, compared with 60% in the cisplatin/cyclophosphamide group 
(P = 0.01). The frequency of surgically verified complete response was similar in the two 
groups (20% for CP and 26% for TP). 
 
Table 3:  Median Progression-Free Survival 
 
REGIME MEDIAN 
PROGRESSION 
FREE SURVIVAL 
95% CI INTERVAL 
Paclitaxel/Cisplatin (TP) 18 months 16 - 21 months 
Cisplatin/Cyclophosphamide (CP) 13 months 11 - 15 months 
 
Progression-free survival was significantly longer (P < 0.001) in the paclitaxel/cisplatin (TP) 
group than in the cisplatin/cyclophosphamide (CP) group (median, 18 vs. 13 months). 
 
Table 4:  Median Survival 
 
REGIME MEDIAN 
SURVIVAL 
95% CI INTERVAL 
Paclitaxel/Cisplatin (TP) 38 months 32 - 44 months 
Cisplatin/Cyclophosphamide (CP) 24 months 21 - 30 months 
 
Survival was also significantly longer (P < 0.001) in the paclitaxel/cisplatin group (median, 
38 vs. 24 months). 
 
The improvement in median progression-free survival is less than half the observed 
improvement in median overall survival. This is an apparent discrepancy. Is the better 
survival due to chance?  It has been suggested that this is due to the unique mode of action 
of the paclitaxel altering the biology of the disease. Alternatively, it may be due to 
responsiveness to second line therapy. 
 
2.2 Conclusion on Direction of Evidence and its Quality 
 
The lack of a blinded assessment of response is the only major methodological weakness of 
this study.  There are a number of small technical deficiencies.  Nevertheless, although it is 
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dangerous to base therapy on a single trial, the results of this trial are impressive, and 
although similar studies are progressing, this particular trial is unlikely to be repeated.   
 
The results are not out of line with the preliminary results and investigations on the drug in a 
number of other solid tumours19 and as second line therapy for cisplatin resistant ovarian 
cancer.20 
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3. COST AND BENEFIT IMPLICATIONS OF ADOPTING INTERVENTION 
 
3.1 Selection of Appropriate Baseline 
 
Since there has been only one RCT focusing on paclitaxel as a first line treatment for 
ovarian cancer, this must form the basis of the clinical evidence for the cost-effectiveness 
analysis. 
 
In performing an economic analysis of paclitaxel it is important to select a suitable baseline 
treatment from which both the increase in clinical benefit due to the proposed new treatment 
and the economic consequences of such a move can be measured. 
 
Based on clinical advice, and the ICON 3 protocol,1 the current UK standard treatment of 
single agent carboplatin has been selected for the purposes of this Guidance Note as the 
baseline for our comparisons with the paclitaxel/cisplatin platinum combination. 
 
3.2 Patient Cohort 
 
In order to calculate the overall potential cost to the Trent region due to TP treatment for 
advanced ovarian cancer it is necessary to consider the number of patients likely to be 
challenged with this regimen. 
  
For the purpose of the cost-effectiveness analysis it has been assumed that 35% of patients 
who present with ovarian cancer will not be challenged with TP. 
 
This estimate is based on expected levels of health status using the ECOG (European 
Clinical Oncology Group) performance status 0 - 2 and good general medical condition, 
rather than age, and is been based on  clinical opinion. It has been assumed that this group 
of patients will continue to use the standard single agent therapy. The estimate also takes 
into account a proportion of patients who would be expected to present with Stage 1, 
surgery only, disease, based on FIGO data. 
 
These factors combine to imply an expected patient cohort of 299 patients per annum within 
Trent. 
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3.3 Treatment Details and Costs 
 
In calculating the cost of treatment the analysis has focused on two specific areas of cost: 
 
1. Direct Treatment - which includes the chemotherapy drugs and supporting treatments 
administered in each of the individual treatment courses; and 
  
2. Adverse Effects - where extra costs are incurred in managing the adverse effects 
caused by the treatments e.g. alopecia, fever etc. 
 
The analysis has been limited to the costs incurred in the first line treatment of ovarian 
cancer.  The treatment regimes have been analysed primarily using local Trent drug costs in 
RUGHUWRSURYLGHFRVWLQJVEDVHGYHU\PXFKLQWKHµORFDO¶FRQWH[W$OVRVWDQGDUG7UHQWFRVWV
for in-patient, out-patient and day case activity have been used. 
 
In deriving the treatment costs it has been assumed that each treatment regime is repeated 
an average of six times for each patient.  
 
A standard body surface area of 1.8m2  has also been assumed in order to calculate the 
correct drug dosages. 
 
The paclitaxel/cisplatin treatment was varied slightly from the original trial regime as a 
number of the supporting drugs would be prescribed and administered slightly differently 
within Trent. However, this has very little effect on total cost as the actual costs of the drugs 
concerned are small when compared to the cost of the chemotherapy drugs cisplatin, 
carboplatin and paclitaxel. 
 
The following tables detail the treatment regimes used for the economic analysis. 
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Table 5: Treatment Details - Paclitaxel/Cisplatin 
 
DRUG DOSE 
Cisplatin 75 mg/m2 (iv) 
Paclitaxel 135 mg/m2 (iv) - 24hr - 
Chlorpheniramine 10 mg (iv) 
Cimetidine 300 mg (iv) 
Granisetron 3 mg (iv) 
Dexamethasone 8 mg (iv) 
Dexamethasone 40 X 2mg tabs 
Average Treatment Cycles = 6 
In-patient Requirement = 2 days 
 
Table 6:  Treatment Details - Carboplatin 
 
DRUG DOSE 
Carboplatin 400 mg/m2 (iv) 
Granisetron 3 mg (iv) 
Dexamethasone 8 mg (iv) 
Dexamethasone 20 X 2mg tabs 
Average Treatment Cycles = 6 
Out-patient Attendance 
 
Details of the specific treatment costings can be found in the Appendix. 
 
3.4 Adverse Effects 
 
As well as the drug costs, it has also been necessary to examine the potential differences 
between treatments of the costs involved in the management of side-effects.  
 
The GOG trial identified a number of potential adverse effects for the paclitaxel/cisplatin 
combination. Of these, two were identified as having potential cost implications which would 
not be expected with single agent carboplatin treatment.  
 
 
These effects were identified as :- 
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Alopecia -  requiring a wig as treatment 
Fever  -  requiring antibiotics and a degree of in-patient stay.  
 
Using the trial data combined with clinical opinion, a percentage risk per patient has been 
derived for each of the effects and a standard Trent cost has been applied. 
 
The following table details the adverse effect data used in the study. 
 
Table 7: Adverse Effects 
 
EFFECT TREATMENT CARBOPLATIN PACLITAXEL/ 
CISPLATIN 
 
  Probability Probability 
Alopecia 
  
Wig  0% 100% 
Fever  Antibiotics    +  In-Patient 
Admission (3 days) 
1% 19% 
 
3.5 Expected Costs 
 
Using the cohort data and the costing information, an overall cost picture for the Trent 
region as a whole and also on a per patient basis can be developed. 
 
Table 8:  Total Expected Costs per Annum 
 
REGIME COST PER PATIENT AVERAGE 
DISTRICT COST 
TRENT REGIONAL 
COST 
Paclitaxel/Cisplatin £10,427 £321,932 £3,108,574 
Carboplatin   £2,059 £63,564   £613,774 
Cost Difference  £8,368 £258,368 £2,494,800 
 
The extra cost per patient between the two treatments is estimated at £8,368.  
 
3XW LQWR WKH FRQWH[W RI WKH 7UHQW UHJLRQ¶V SUHYDOHQFH UDWHV DQG IHPDOH SRSXODWLRQ WKLV
implies an increase in total treatment costs of  just under  £2.5 million per annum. For an 
average district of 250,000 females this equates to an increase of around £258,368.  
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3.6 Treatment Benefits 
 
In terms of treatment benefits, this Guidance Note has concentrated on the two particular 
output measures linked to the detailed outcomes from the GOG trial. 
 
x Life Years Gained (LYG) - A measure, in years, of the expected increase in 
survival time from randomisation. 
 
x Progression Free Years 
Gained (PFYG) 
- A measure, in years, of the expected increase in the 
period of time from randomisation to the beginning of 
clinical progression. This is in effect a measure of life 
years gained which implies a quality health state. 
(Although it is noted that patients in clinical progression 
can still have a period of disease which brings little 
disruption to their daily lives). 
 
The benefits for the paclitaxel/cisplatin treatment have been taken directly from the median 
point values published in the GOG trial results.  
 
Unfortunately, no direct RCT trial comparison of carboplatin to paclitaxel/cisplatin exists. 
Therefore, in order to derive suitable data on clinical benefits for carboplatin, two options 
present themselves: 
 
Option 1. To use supporting data collated and derived from a number of smaller 
independent RCT trials which have focused on carboplatin versus a number of 
other alternative treatment regimes. This approach has a risk in that the existing 
trial data on carboplatin are not always directly comparable due to differences in 
trial design and entry criteria. Therefore, any calculation of data would be 
pragmatic. This is the approach taken by the Wessex DEC report3 to be 
discussed later.  
  
Option 2. To use clinical judgement of comparative trial data, ICON 2, to enable the control 
arm benefits in the GOG trial to be used as a proxy for those of carboplatin. This 
has the benefit of keeping the comparison data within the same trial structure, but 
carries the possible danger of over-estimating the benefits of carboplatin. 
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Within the main analysis Option 2 has been used, as it was felt that any acceptance of 
SDFOLWD[HO XQGHU WKHVHFRQGLWLRQVZRXOGEHEDVHGRQDVWURQJDVVXPSWLRQRIFDUERSODWLQ¶V
benefits.  However, sensitivity results using Option 1 have also been considered. 
 
The clinical benefits for carboplatin were derived based on the interim findings of the       
ICON 221  trial, originally designed to compare carboplatin against the platinum combination 
CAP, and the results of available trial evidence comparing CAP with CP treatment.   
 
The interim trial results of ICON 221  have pointed towards a possible survival and 
progression free benefit in using the platinum combination CAP rather than single agent 
carboplatin. However, there is no definite statistical proof of this effect and, importantly, 
confidence intervals at this stage are still wide and cross unity. Indeed, as more data 
become available from the ICON 221 trial, the strength of this evidence for CAP appears to 
be diminishing. Therefore, until ICON 221  reports in full on this issue the working assumption 
is that carboplatin should be considered to be as effective as CAP or any other standard 
platinum combination therapy. 
 
Evidence comparing CAP with CP directly is limited and inconclusive. While evidence from 
the original GOG 52 trial and the Ovarian Cancer Project meta-analysis9 did suggest CAP 
as being more beneficial, the scale and strength of this evidence is limited. It is currently felt 
that the difference here is marginal and must be considered in the light of the increased 
toxicity of the CAP treatment. Therefore, in our analysis we have considered CAP as having 
a similar efficacy to CP.  
 
In summary, by using the CP arm benefits from the GOG 111 trial as an indication of 
FDUERSODWLQ¶V SRWHQWLDO EHQHILWV WKH SDSHU LV DOPRVW FHUWDLQO\ EHLQJ RYHU VXSSRUWLYH RI WKH
current standard treatment. It is likely that CP does provide increased benefits over 
carboplatin, however, the current evidence fails to prove this conclusively. 
 
3.7 Life Years Gained Benefits 
 
The following clinical benefits have been derived from the survival outcomes of the GOG 
trial. Lower and upper levels for the 95% Confidence Interval (CI) have been provided. 
 
Table 9: Life Years Gained Comparison 
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 REGIONAL LEVEL  PER PERSON  
   Lower Median Upper Lower Median Upper 
Paclitaxel/Cisplatin 499.02 592.59 686.16 2.67 3.17 3.67 
Carboplatin 327.48 374.27 467.83 1.75 2.00 2.50 
 
Median LYG Difference  
 
218.32 
 
(31.19-358.67) 
 
1.17 
  
(0.17-1.92) 
 
The Median LYG Difference compares the two median point estimates. The confidence 
intervals are provided in the bracketed figures based on the trial data. 
 
This implies a Number Needed to Treat to gain an extra 1 LYG of  0.86  (range 0.52 - 
6.00). 
 
3.8 Progression Free Years Gained  
 
The following benefits have been derived from the progression free outcomes of the trial. 
Lower and upper levels for the 95% CI have been provided. 
 
Table 10: Progression Free Years Gained Comparison 
 
 REGIONAL LEVEL  PER PERSON  
   Lower Median Upper Lower Median Upper 
Paclitaxel/Cisplatin 249.51 280.70 327.48 1.33 1.50 1.75 
Carboplatin 171.54 202.73 233.92 0.92 1.08 1.25 
 
Median LYG Difference  
 
77.97 
 
(15.59-155.94 ) 
 
0.42 
 
(0.08-0.83) 
 
The Median LYG Difference compares the two median point estimates. The confidence 
intervals are explored in the bracketed figures based on the trial data. 
 
This implies a Number Needed to Treat to gain an extra 1 PFYG of 2.4 (range 1.2 - 12.0). 
 
3.9 Cost-effectiveness 
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The following table lists the cost-effectiveness of using paclitaxel/cisplatin over the current 
standard treatment of carboplatin. The calculations are based on the expected increase in 
median clinical benefit and link this with the expected increase in cost per patient between 
the treatments. 
 
Table 11: Cost per extra Life Year Gained 
 
(A) Extra LYG per person  1.17  
(B) Extra Treatment Cost per person   £8,368    
 
(B/A) 
 
Cost per Extra LYG 
  
£7,173  
 
(£4,366 -£50,209) 
 
The bracketed figures provide the values at around the confidence intervals. 
 
Table 12 : Cost per extra Progression Free Year Gained 
 
(A) Extra PFYG per person  0.42  
(B) Extra Treatment Cost per person   £8,368    
 
(B/A) 
 
Cost per Extra PFYG 
  
£20,084  
 
(£10,042-  £100,418) 
 
The bracketed figures provide the values at around the confidence intervals. 
 
On the basis of this analysis there is an obvious clinical benefit from using a 
paclitaxel/cisplatin combination therapy in first line ovarian cancer treatment, although this is 
still very much based on the results of a single phase III RCT. 
 
The extra cost of such a treatment is significant to Trent as a region at a figure of 
approximately £2.5 million per annum. 
 
In terms of extra LYG the treatment is expected to give each patient an average of 1.17 
\HDUV¶H[WUDVXUYLYDO7KLVHTXDWHV WRDFRVWSHUH[WUD/<*RIDSSUR[LPDWHO\ZKLFK
compares favourably with other treatments. The figure is below the £20,000 threshold often 
quoted as the breakpoint for recommended treatments. 
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The cost per extra PFYG is provided to give an extra dimension to the analysis which 
focuses the benefit more towards a quality survival. 
 
3.10. Sensitivity Analysis 
 
In order to expand on the analysis and to explore the cost-effectiveness further the results 
have been considered under a set of different scenarios. Under each scenario the 
calculated cost per extra LYG is shown. 
 
3.10.1 Scenario Analysis 
 
The scenarios explore the use of national costs, increases in relative adverse effects costs 
DQGWKHFDOFXODWLRQRIFDUERSODWLQ¶VFOLQLFDOEHQHILWVIURPVHSDUDWHWULDOVRXUFHV 
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Table 13: Results of Sensitivity Analysis 
 
SCENARIO COST PER 
EXTRA LYG 
BASECASE set to current cost benefit analysis  £7,173 
1. Using standard national pharmaceutical costs instead of Trent costs  £6,663 
2. Using carboplatin benefits at 20 months (as in the Wessex DEC report 3)  £5,579 
3. Using carboplatin benefits at 28 months (increase benefits of carboplatin from 
24 months) 
£10,042 
4. Increasing hospital IP/OP costs by 100%  £9,333 
5. Increasing hospital IP/OP costs by 400% £13,649 
6. Increasing adverse effects costs for paclitaxel by 100%  £7,264 
7. Increasing adverse effects costs for paclitaxel by 400%  £7,443 
8. Combination of scenarios 1, 2  £5,183 
9. Combination of scenarios 1, 3  £9,329 
10. Combination of scenarios 3, 5  £19,098 
11. Combination of scenarios 3, 5 and 7 £19,476 
12. Increase the cost of paclitaxel by 100% £13,099 
  
Overall, the scenario analysis indicates that the cost-effectiveness measures are reasonably 
robust to quite dramatic variations in expected benefits and in expected drug and 
management costs. The use of national costs actually strengthens the arguments for 
paclitaxel. Even an increase of 100% in the cost of paclitaxel fails to damage the cost- 
effectiveness argument. 
 
3.10.2  Analysis of Cost per Extra Life Year Gained  
 
The following tables assist in exploring further the underlying assumptions made in deriving 
the median survival data, in order to provide a better feel for the degree of overall effect that 
these underlying assumptions have on clinical benefit. The analysis has been performed 
using the original Trent costings.  
 
 22 
Table 14: Analysis of Carboplatin Benefit Assumptions  
Question : If the paclitaxel/cisplatin treatment benefit and costs remained constant, what 
would the carboplatin benefits have to be to imply the costs per extra LYG as 
listed? 
COST PER 
EXTRA 
LYG 
PACLITAXEL/CISPLATIN 
MEDIAN SURVIVAL 
(months) 
IMPLIED 
DIFFERENCE IN 
MEDIAN SURVIVAL 
(months) 
IMPLIED 
CARBOPLATIN 
MEDIAN SURVIVAL 
(months)  
£10,000 38  10 28 
£20,000 38 5 33 
£30,000 38    3.4    34.6 
£40,000 38    2.5    35.5 
£50,000 38 2 36 
 
Table 15: Analysis of Paclitaxel/Cisplatin Benefit Assumptions  
Question :  If the carboplatin treatment benefit and costs remained constant what would 
the paclitaxel/cisplatin benefits have to be to imply the costs per extra LYG as 
listed? 
COST PER 
EXTRA 
LYG 
CARBOPLATIN 
MEDIAN SURVIVAL 
(months) 
IMPLIED DIFFERENCE 
IN MEDIAN SURVIVAL 
(months) 
IMPLIED 
PACLITAXEL/CISPLATIN 
MEDIAN SURVIVAL 
(months) 
£10,000 24 10 34 
£20,000 24 5 29 
£30,000 24    3.4    27.4 
£40,000 24    2.5   26.5 
£50,000 24 2 26 
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Table 16: Analysis of Paclitaxel/Cisplatin Benefit Assumptions Based on a 
  20 month Carboplatin Benefit  
Question :  If the carboplatin treatment benefit remained constant at the 20 month level 
and costs also remained constant, what would the paclitaxel/cisplatin benefits 
have to be to imply the costs per extra LYG as listed? 
COST PER 
EXTRA 
LYG 
CARBOPLATIN 
MEDIAN SURVIVAL 
(months) 
IMPLIED DIFFERENCE 
IN MEDIAN SURVIVAL 
(months) 
IMPLIED 
PACLITAXEL/CISPLATIN 
MEDIAN SURVIVAL 
(months) 
£10,000 20 10 30 
£20,000 20 5 25 
£30,000 20    3.4    23.4 
£40,000 20    2.5    22.5 
£50,000 20 2 22 
 
Given that the costs used in the analysis remain as expressed in the report, the critical 
difference in clinical benefit between the two treatments arms is five months. Below this 
difference the cost per extra LYG exceeds the £20,000 which would typically put the 
treatment in a high cost recommended category. Considering the current analysis is using a 
difference of 14 months (TP 38 months / Carboplatin 24 months) this suggests that the  
cost-benefit results are reasonably robust to any possible changes in the clinical benefit 
data. The benefits of TP would have to reduce by around 23% before crossing the £20,000 
conceptual barrier. Likewise, the CP benefits would have to increase by around 37%. 
 
3.10.3  Sensitivity Summary 
 
In summary, the sensitivity analysis suggests that, given the existing treatment costs and 
clinical benefits, the overall cost-benefit between the treatments remains consistently below 
the £20,000 per extra LYG mark. This is encouraging as it provides a level of confidence in 
the overall effects of the key assumptions made in the analysis around the clinical benefits 
of carboplatin and the cost of adverse effects.  
 24 
3.11. Summary of Existing Economic Evidence 
 
6LQFH WKH SXEOLFDWLRQ RI WKH *2*  5&7 UHVXOWV DQG WKH 7UHQW :RUNLQJ *URXS¶V LQLWLDO
analysis, there have been two further sets of economic analyses published which consider 
the cost-benefit case for the use of paclitaxel as a first line treatment. Due to the fact that 
the GOG 111 trial is the only RCT available, these analyses are based on the same source 
data, however, each has its own individual approach. The reports are discussed below. 
 
3.11.1 Wessex DEC Report No 563 µ3DFOLWD[HO DV D )LUVW /LQH &KHPRWKHUDS\
$JHQWLQWKH7UHDWPHQWRI2YDULDQ&DQFHU¶ 
 
The report compares three possible treatments (paclitaxel/cisplatin, carboplatin and CAP)  
IRURYDULDQFDQFHUZLWKDEDVHOLQHDVVXPSWLRQRIµ1R7UHDWPHQW¶ 
 
The benefits of the individual treatments have all been based on median survival times. The 
clinical benefits of paclitaxel/cisplatin have also been sourced directly from the GOG 111 
paper. However, the individual benefits of the CAP and carboplatin treatments have been 
derived from the combination of a number of smaller published RCT trials. The exact 
methodology for combining these data is not clear from the report itself. The report also 
highlights that there are a number of issues with regard to extracting data in this way due to 
differences between trial design and the treated cohorts. 
 
Table 17: Wessex DEC Median Survival Data 3  
 
TREATMENT MEDIAN SURVIVAL 
Carboplatin 20 months 
CAP 24 months 
Paclitaxel/Cisplatin 38 months 
No Treatment   6 months 
 
The cost-benefit analysis uses the concept of QALYs as a benefit measure. This 
methodology uses a measure of quality of life to patients in order to adjust or weight the 
standard LYG values. This approach has not been followed in our analysis. 
 25 
 
In analysing the cost-EHQHILWVZKHQFRPSDULQJ WRDEDVHOLQHRI µ1R7UHDWPHQW¶ WKHUHSRUW
indicates that paclitaxel/cisplatin provides an extra 200 QALYs per 100 patients at a cost of 
£868,000.  
This equates to a cost of £4,340 per extra QALY as can be seen in the table below. 
 
Table 18: Wessex DEC Cost Benefits - No Treatment Baseline3 
 
COSTS AND BENEFITS Paclitaxel and Cisplatin Carboplatin 
Cost per 100 patients £868,000 £288,000 
Extra QALYs gained per 100 
SDWLHQWVDERYHµ1R7UHDWPHQW¶
baseline 
200 90.5 
Cost per extra QALY £4,340 £3,180 
 
Using these figures to calculate the extra cost benefit of paclitaxel/cisplatin when comparing 
to the baseline of carboplatin treatment, a figure of £5,297 per QALY is generated. 
 
Table 19: Wessex DEC Cost Benefits - Carboplatin Baseline3 
 
COSTS AND BENEFITS Paclitaxel and Cisplatin Carboplatin 
Extra Cost per 100 patients 
above Carboplatin 
£580,000 - 
Extra QALYs gained per 100 
patients above Carboplatin 
baseline 
109.5 - 
Cost per extra QALY £5,297 - 
The Wessex DEC3 concludes that the clinical evidence for paclitaxel does exist and the 
cost-benefit analysis rates the treatment as recommended, against its own judgement 
scale, along with the standard treatments of CAP and carboplatin. However, reference is 
made to the fact that the clinical benefit data used in the analysis come from a range of 
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independent sources and that the underlying evidence for paclitaxel is also based on a 
single trial.  
 
In view of this, the recommendation has also proposed a later review in the light of the final 
publication of RCT evidence from ICON 221 and 31 and other possible trials.  
 
3.11.2  GOG 111 Cost-effectiveness Paper  
 
This GOG economic analysis is again based on the direct results of the GOG 111 RCT and 
reflects the overall costs taken in a US setting. The resource implications are derived from 
the trial itself with supporting clinical opinion in order to put a non-WULDOµUHDOZRUOG¶YLHZWRWKH
cost analysis. The costs used in the analysis covered a wide range of direct costs:- 
 
x pharmaceutical costs 
x physician costs 
x laboratory and diagnostic costs 
x adverse reaction management costs 
x in-patient/out-patient costs 
x follow-up costs.  
 
Costs were limited to the direct treatment costs and did not extend to cover the cost of 
future treatments. The analysis was performed using the median point survival data and the 
equivalent mean survival data. This was done as it was felt that, although clinically relevant, 
the median survival data may tend to over-estimate the cost-efficiency ratios. These data 
were obtained directly from the GOG statistical office and advice was taken to avoid any 
conflicts of interest in the analysis. 
 
Interestingly, the analysis considered the mean survival data using figures up to the end of 
the trial period and on the basis of a present day measure by considering post trial survival 
rates. 
The analysis concluded that, based on GOG 111 mean survival data (to present time), the 
extra cost per LYG for TP is estimated to be £6,534 ($10,454 @  $1.60=£1) above that of 
the CP arm.  
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The analysis concluded that, based on GOG 111 mean survival data (to end of trial), the 
extra cost per LYG for TP is estimated to be  £12,388 ($19,820 @  $1.60=£1) above that of 
the CP arm.  
 
The analysis concluded that, based on GOG 111 median survival data, the extra cost per 
LYG for TP is estimated to be  £5,827 ($9,323 @  $1.60=£1) above that of the CP arm. 
 
A separate multivariate Monte Carlo analysis was also performed which varied the mean 
survival time (to end of trial) around the published values using sets of unspecified 
distributions. This extra analysis provides an expected distribution of the extra cost per LYG 
of  £12,417 r £680 ($19,868 r $1087). 
 
The conclusion of the analysis was that the TP treatment fell within the accepted criteria for 
it to be deemed as being a cost-effective treatment. 
 
However, in critically reviewing this paper from a health economics perspective, there are a 
number of issues which throw some doubt as to the relative strength of evidence this 
represents in terms of a UK based treatment. 
 
x Analysis is based on a wide range of clinical assumptions which may not necessarily 
hold true in the UK setting, particularly those in relation to adverse effects management. 
  
x A number of similarities are assumed between the two treatments with approximately 
46% of the costs identical for both treatments.  
  
x The analysis does not bring in the wider range of indirect costs and community costs 
which may impact on the cost-effectiveness argument.  
  
x The analysis is necessarily made using the CP treatment as the baseline, which is not 
representative of the standard UK treatment of carboplatin as a single agent.  
  
7KHFRQFOXVLRQ LQWHUPVRIWKHSDSHU¶VUHOHYDQFH LVWKDWZKLOVWWKHUHVXOWVSURYLGHIXUWKHU
HYLGHQFHDV WRSDFOLWD[HO¶VFRVW-effectiveness, with an extra cost per LYG of £12,388, it is 
certainly not enough in isolation to imply expected treatment costs within  the UK. 
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However, the paper does add to the evidence gained from both the Wessex3 analysis and 
7UHQW¶V RZQ ZRUN ZKLFK KDYH EHHQ EDVHG ZLWKLQ WKH FRQWH[W RI 8. FRVWV DQG VWDQGDUG
treatment comparitors.  
 
3.12. Calculation of Survival Benefits Based on Survival Curve 
 Estimates 
 
It is interesting to note that the two economic analyses published have both approached the 
measurement of the clinical benefit of the treatments using a standard median point 
measure. 
 
An alternative to this methodology is to focus not on median or mean data points, which are 
essentially single point estimates, but to look more at the complete experience of the cohort 
via the area under the survival curve (AUC). 
 
Therefore, to provide an extra added value to the cost-effectiveness analysis a second 
economic evaluation has been compiled using AUC estimated survival benefits. 
 
The survival data have been derived directly from the GOG 111 paper using the published 
survival curves.  
 
Using these data a Weibull curve has been fitted to the survival data for both treatments. 
This was achieved using a method of minimising the sum of the squared differences 
between the fitted curve and the observed values via a statistical curve fitting routine in 
Microsoft Excel. 
 
The fitted curves provided area under the curve, AUC, estimates for both treatments   
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Figure 1: Curve estimates of Survival Data 
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The curves have been extrapolated beyond the 48 months of trial data to estimate potential 
future benefits; a limit of 90 months was fixed on this forward projection.  
 
There are obvious problems with uncertainty when projecting a fitted curve forward in time 
as it is necessary to make the assumption that the form of the curve will remain the same 
over time, this may or may not be the case. Therefore, the results are expressed for  
scenarios which include or exclude the forward looking projection. 
 
Table 20: Area Under Curve - Estimates 
 
TREATMENT AUC to 48 months AUC to 90 months 
TP 2.78 LYG 3.43 LYG 
CP 2.25 LYG 2.67 LYG 
Difference 0.53 LYG 0.76 LYG 
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Table 21: Area Under Curve - Costings 
 
TREATMENT AUC to 48 months AUC to 90 months 
Extra Cost per 
patient 
 £8,368  £8,368 
Extra LYG per 
patient 
0.53 LYG 0.76 LYG 
Cost per extra 
LYG  
£15,788 £11,010 
 
Compared to the initial analysis based on median point survival data, using a fitted Weibull 
curve estimate of the survival data decreases the overall relative benefits of paclitaxel 
although they still remain significant.  
 
The cost per marginal LYG increases from £7,173 to a value of £15,788. However, when the 
AUC is considered over a period beyond the trial period the value does return to a projected 
level of £11,010 per extra LYG.  
 
These alternative AUC estimated cost per extra LYG values still remain within the 
recommended category guidelines. 
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4. OPTIONS FOR PURCHASERS AND PROVIDERS 
 
The current published clinical evidence points strongly towards there being a clear benefit 
from the use of paclitaxel/cisplatin as a first line treatment for ovarian cancer.  
 
Also, the economic cost-benefit analysis further supports the treatment with a cost per life 
year gained which is comparable with other existing treatments. 
 
Interestingly, the recent Wessex DEC report3 similarly compares both paclitaxel/cisplatin 
DQGFDUERSODWLQWRDµ1R-7UHDWPHQW¶EDVHOLQH7KLVUHSRUWZDVDOVREDVHGRQWKH*2*WULDO
as this is the only phase III RCT available. Using a Quality of Life, rather than LYG, 
approach to their economic analysis, they too have supported the treatment as a 
recommended therapy. 
 
There are a number of issues concerning the use of paclitaxel as a first line treatment which 
are either the focus of general clinical discussion or are being addressed via current RCTs. 
 
Firstly, there are still issues to be answered about possible second line treatment options, as 
these could impact on paclitaxel costs if paclitaxel were re-administered to patients where 
first line treatment had failed. The conventional treatment option for patients with relapsed 
disease is to re-treat them with the agent to which they first responded. Patients with 
progressive disease, or that responsive to platinum agents, may be given a second line 
agent. The treatment response to disease progression after failed first line paclitaxel is yet 
to be determined. It is assumed in this paper that patients with relapsed disease will be 
offered one of the current platinum or second line agents and not be re-challenged with 
paclitaxel. 
 
Secondly, four phase III RCTs are currently underway looking further at paclitaxel as a first 
line treatment for ovarian cancer. 
 
Trial Treatment Arms 
1. GOG 132 trial x cisplatin 
x paclitaxel 
x paclitaxel/cisplatin 
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Trial Treatment Arms 
2. GOG 114 trial x cisplatin/cyclophosphamide 
x paclitaxel/cisplatin 
x carboplatin/paclitaxel/cisplatin 
 
3. EORTC/NIC trial x paclitaxel(3 hour)/cisplatin 
x cisplatin/cyclophosphamide 
 
4. ICON 31(MRC) x carboplatin 
x paclitaxel (3 hour)/ carboplatin 
x CAP 
 
Further issues now being explored around the use of paclitaxel include :- 
 
x length of the infusion; 
x optimum dose intensity; 
x optimum number of cycles; and  
x combination with carboplatin. 
 
A number of centres have begun to use a short three hour duration paclitaxel infusion which 
allows day case therapy; this is based on the results of a European-Canadian study of 
paclitaxel in relapsed ovarian cancer.22  The efficacy of the three hour regime has not yet 
been verified for primary chemotherapy. 
 
Finally, the possibility of using a paclitaxel/carboplatin combination has been investigated 
with a phase I evaluation using  3- (175 mg/m2), 24- (135 mg/m2) and 96- (120 mg/m2) 
hour regimes. The 96 hour regime was abandoned due to excessive myelosuppression.  
Overall response rate was 75% (n=24) with a median progression free survival time of 15 
months.23 Another phase I study also concluded that paclitaxel (185 mg/m2) given with 
carboplatin could be administered safely.24 In patient terms this type of treatment would 
reduce the need for in-patient care and reduce the side effects related to cisplatin.  
 
:LWKLQ 7UHQW¶V DQDO\VLV D VHFRQGDU\ VXSSRUWLYH VHW RI HFRQRPLF HYDOXDWLRQV KDV EHHQ
performed based on a paclitaxel/carboplatin combination therapy. However, based on the 
current drug costs and assuming the same expected clinical benefits as with the 
paclitaxel/cisplatin combination, this treatment is still less cost-effective in the long run (Cost 
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per extra  LYG per person = £8,400 compared to £7,200 for TP). Also, it is important to 
stress that no published phase III evidence exists for the efficacy of carboplatin/paclitaxel. 
 
In the light of such existing evidence purchasers are faced with three possible options: 
 
1. To continue with the standard UK treatments and wait for further supportive evidence of 
SDFOLWD[HO¶VFOLQLFDOHIIHFWLYHQHVV 
  
2. To continue with current standard treatments but engage in the ICON 31 trial, with 
suitable patients, in order to provide paclitaxel treatment. (The ICON 31 trial is recruiting 
2,000 patients in total and is rapidly filling its patient cohort).  
  
3. To engage in the ICON 31 RCT and also fund paclitaxel treatment for suitable patients 
outside the trial, in support of existing first line treatments based on carboplatin and 
CAP. 
 
A further issue which purchasers should consider is the current pricing strategy adopted by 
Bristol Myers regarding paclitaxel. Currently the US are benefiting from a 30% discount on 
standard costs compared to the rest of the world. There is potential for a similar discounting 
to be experienced in the UK, particularly if paclitaxel is adopted as a first line treatment and 
pharmaceutical contracts are negotiated effectively.  
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5. DISCUSSION AND CONCLUSION 
 
The key concern about the current evidence is that there is at present only one single 
published RCT trial, GOG 111. There is also some concern expressed by a group of 
clinicians around the choice of control treatment used in the GOG 111 trial, as the US 
standard treatment differs from that of the UK. Within the economic analysis the UK base 
treatment of carboplatin has been used as the comparitor, as identified in the ICON 31 
protocol.  
 
The EORTC trial is beginning to demonstrate a clear clinical benefit of using 
paclitaxel/cisplatin versus CP with a 4.6 month difference in progression-free survival 
between the two arms in favour of paclitaxel/cisplatin. This effect was reported at the 
median 20 month follow-up period. These preliminary, and as yet unpublished, results are 
likely to confirm the benefits of GOG 111. 
 
The forthcoming publication of ICON 221 and later the ICON 31 trial, will hopefully provide a 
clearer picture of the benefits of paclitaxel in the UK setting. 
 
The GOG 132 trial has provided a first interim report which is less conclusive showing no 
benefit for paclitaxel/cisplatin. The trial compares paclitaxel/cisplatin versus two control arms 
- single agent cisplatin and single agent paclitaxel. Importantly, the allowed crossover 
between the control arms can be argued strongly to cloud interpretation and as such must 
be viewed with some care. 
 
In conclusion, the clinicians would argue strongly that the evidence base is sufficiently 
strong to support the purchase of paclitaxel and cisplatin combined therapy as a first line 
treatment for ovarian cancer, with opportunity to review after the publication of ICON 3.1 
However, the purchasers on the Working Group do not feel able to endorse fully this view 
until the findings of GOG 111 have been confirmed, although they do fully support the 
ongoing ICON 31 trial. 
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6. USE OF PACLITAXEL AND CISPLATIN IN THE TREATMENT OF OVARIAN CANCER : SUMMARY MATRIX 
 
T PATIENT GROUP PATIENT CRITERIA 
(GUIDELINES NOT PROTOCOLS) 
ESTIMATED 
FUTURE 
ACTIVITY 
OPPORTUNITY 
FOR COST 
SAVING 
AUDIT POINTS EFFECTS THAT COULD BE 
EXPECTED IN RELATION 
TO STARTING POINT 
 
COST-EFFECTIVENESS 
Patients with stage 
II/III/IV ovarian 
cancer. 
 
 
 
 
 
 
 
 
 
Likely to be used for patients who are 
<65 years of age and who are 
functionally suitable for treatment. 
Expected 
annual activity 
of 299 cases 
within Trent . 
 
(31 cases in a 
typical district of 
size 500,000). 
None. Continued 
review of 
survival and 
progression-
free survival 
rates. 
 
Recording of 
adverse 
effects, 
especially 
those  which 
imply cost. 
Increased median survival 
and an increase in 
progression-free survival 
compared to the current UK 
base treatment. 
 
A projected extra LYG of 
1.17 per patient. 
Costs per extra LYG  above the 
current standard treatment of 
single agent carboplatin. 
 
£7,173 per LYG . 
 
Cost  per extra PFY above the 
current standard treatment of 
single agent carboplatin. 
 
£20,084 per PFY. 
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APPENDIX : COSTING INFORMATION 
 
Drug Costs 
 
 
Drug Dosage 
 
Trent 
Cost 
UK 
COST 
A Cisplatin - iv 135mg £39.66 - 
C Paclitaxel - iv 240mg £1173.04 - 
E Chlorpheniramine - iv 10mg £0.14 - 
F Cimetidine - iv 300mg £0.61 - 
G Carboplatin - iv 720mg £271.02 £371.26 
H Cyclophosphamide 900mg £3.64 £4.80 
J Doxorubicin 90mg £146.84  
K Granisetron - iv 3mg £9.99 £42.30 
L Dexamethasone - oral 40 X 2mg tablets £1.72 £4.06 
M Dexamethasone - iv 8mg £0.70 £2.07 
 
 
Hospital Costs 
 
A Day Case Treatment £206 
B Out-Patient  Treatment £59 
C In-Patient Treatment £229 
 
 
Management of Adverse Effects - Drug Costs 
 
A Alopecia  £69 
B Allergic Reaction £10 
C Fever  £200 
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